Surgical and pharmaceutical treatment of superficial vein thrombosis of the lower limbs: what has changed over the last 5 years?

被引:0
|
作者
Papageorgopoulou, Chrysanthi [1 ]
Nikolakopoulos, Konstantinos [1 ]
Papageorgopoulou, Aspasia [2 ]
Seretis, Charalampos [1 ,3 ]
机构
[1] Univ Gen Hosp Patras, Dept Vasc Surg, Rion 26504, Achaia, Greece
[2] Aghios Andreas Gen Hosp Patras, Dept Gen & Vasc Surg, Rion, Greece
[3] Univ Warwick, George Eliot Hosp NHS Trust, Med Sch, Warwick, England
关键词
anticoagulation; heparin; superficial vein; surgery; venous thrombosis; THROMBOPHLEBITIS; FONDAPARINUX; RIVAROXABAN; MANAGEMENT; OUTCOMES; HEPARIN; PLACEBO; LEG;
D O I
10.5604/01.3001.0015.9280
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Superficial vein thrombosis of the lower limbs is a common condition encountered by a wide spectrum of clinical specialties. In contrast to deep vein thrombosis of the lower limbs though, there is significant variability in terms of its treatment with respect to the type and duration of pharmacotherapy, as well as regarding the potential role of operative management. Materials and methods: Systematic review of the literature in a best evidence topic manner, including only prospective and randomized controlled studies on the treatment of lower limb SVT, focusing on the emerged data over the last 5 years. Results: A total of 17 prospective observational and randomized clinical studies met our set criteria.Despite the major differences in study designs, outcomes and intervention types, upfront pharmaceutical treatment with fondaparinux or intermediate dose of low molecular weight heparins, combined with regular clinical and radiological follow-up, seem to be effective and safe as first-line approaches. Upfront surgical treatment of lower limb SVT can also be safely performed in selected cases in the presence of clinical expertise. Conclusion: Our review revealed the presence of considerable variability in the therapeutic options of the lower limb superficial venous thrombosis, highlighting the need for further randomized controlled trials in the field in order to establish and standardize its optimal treatment.
引用
收藏
页码:62 / 67
页数:6
相关论文
共 5 条
  • [1] Every day mitral valve reconstruction: What has changed over the last 15 years?
    Motazedian, Farnoosh
    Ostovar, Roya
    Hartrumpf, Martin
    Schroter, Filip
    Albes, Johannes M.
    PLOS ONE, 2022, 17 (10):
  • [2] How has the treatment of hypercholesterolemia in Poland changed over the last six years?
    Kaplon-Cieslicka, Agnieszka
    Michalak, Marcin
    Koltowski, Lukasz
    Filipiak, Krzysztof J.
    CARDIOLOGY JOURNAL, 2017, 24 (03) : 266 - 275
  • [3] What has changed in the last 25 years in osteosarcoma treatment? A single center experience
    Ataseven, Eda
    Goktepe, Sebnem Onen
    Kaya, Huseyin
    Tamsel, Ipek
    Kececi, Burcin
    Argin, Mehmet
    Doganavsargil, Basak
    Sabah, Dundar
    Burak, Zeynep
    Kantar, Mehmet
    TURKISH JOURNAL OF PEDIATRICS, 2023, 65 (01) : 54 - 63
  • [4] Our experience in the surgical management of craniofacial fibrous dysplasia: what has changed in the last 10 years?
    Valentini, V.
    Cassoni, A.
    Terenzi, V.
    Della Monaca, M.
    Fadda, M. T.
    Zadeh, O. Rajabtork
    Raponi, I.
    Anelli, A.
    Iannetti, G.
    ACTA OTORHINOLARYNGOLOGICA ITALICA, 2017, 37 (05) : 436 - 443
  • [5] How has the qualification of patients for transcatheter aortic valve implantation changed over the last 5 years in a single, high-volume center in Poland?
    Marzec, Karolina
    Jaworska-Wilczynska, Maria
    Witkowski, Adam
    Hryniewiecki, Tomasz
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2020, 16 (04): : 477 - 481